CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma
CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell
lymphoma who haven't experienced improvement with chemotherapy treatments